Atea Pharmaceuticals’ treatment of disease caused by dengue virus was granted FDA orphan status, according to a post to the agency’s website.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AVIR:
- Atea Pharmaceuticals’ combination candidate for hepatitis C shows protential
- Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023
- Atea Pharmaceuticals reports Q3 EPS (40c), consensus (48c)
- Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
- Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences
